Document Detail

Asthma-related health care resource use among patients starting fluticasone or montelukast therapy.
MedLine Citation:
PMID:  16305295     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVES: To compare patterns of asthma-related health care resource use among patients prescribed fluticasone or montelukast as singlecontroller therapy for asthma, and to confirm patterns previously observed in retrospective analyses examining outcomes among patients receiving fluticasone or montelukast for asthma. DESIGN: Retrospective cohort study. DATA SOURCE: Administrative claims data drawn from United States health insurers in 35 states, covering 17 million privately insured patients. PATIENTS; A total of 4758 patients aged 2-55 years with asthma who were prescribed either fluticasone or montelukast from July 1, 1998-June 30, 1999, were continuously enrolled for at least 24 months, had no evidence of controller therapy for 6 months before the start of drug therapy, and had no evidence of chronic obstructive pulmonary disease or other respiratory illness. MEASUREMENTS AND MAIN RESULTS: Patients were identified using an algorithm based on medical and pharmacy insurance claims. Patients were matched between groups based on a propensity score of clinical characteristics and age; this resulted in 1512 patients/treatment group. Asthma-related health care claims incurred for 12 months before and after the start of controller therapy were analyzed. After adjustment, the fluticasone-treated group had greater risk than the montelukast-treated group of requiring therapy with a short-acting beta-agonist in the follow-up period (relative risk 1.12, 95% confidence interval [CI] 1.03-1.20). Odds were similar across treatment groups for needing an emergency department visit and/or hospitalization (odds ratio 1.08, 95% CI 0.74-1.58) and for needing therapy with an oral corticosteroid (odds ratio 1.02, 95% CI 0.84-1.26). CONCLUSION: The start of therapy with either fluticasone or montelukast as a single-controller for asthma was associated with similar asthma-related health care resource use in this matched population.
Felicia C Allen-Ramey; David T Anstatt; Shiva G Sajjan; Leona E Markson
Related Documents :
16305295 - Asthma-related health care resource use among patients starting fluticasone or monteluk...
7633875 - Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with p...
9714905 - Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunogl...
9558165 - Slicc/acr damage index in afro-caribbean patients with systemic lupus erythematosus: ch...
19579205 - Early results of the birmingham mid-head resection arthroplasty.
5212355 - Late results of aortic valve replacement with the starr-edwards prosthesis.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacotherapy     Volume:  25     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-24     Completed Date:  2006-04-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1752-60     Citation Subset:  IM    
Outcomes Research and Management, Merck & Co., Inc., West Point, Pennsylvania 19486-0004, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / economics*,  therapeutic use
Androstadienes / economics*,  therapeutic use
Anti-Asthmatic Agents / economics*,  therapeutic use
Asthma / drug therapy,  economics*
Child, Preschool
Cohort Studies
Health Services / utilization*
Middle Aged
Quinolines / economics*,  therapeutic use
Retrospective Studies
Reg. No./Substance:
0/Acetates; 0/Androstadienes; 0/Anti-Asthmatic Agents; 0/Quinolines; 158966-92-8/montelukast; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low-dose vitamin K to augment anticoagulation control.
Next Document:  Pharmacotherapy for human immunodeficiency virus-associated nephropathy.